Compare COCO & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COCO | EWTX |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.7B |
| IPO Year | 2021 | 2021 |
| Metric | COCO | EWTX |
|---|---|---|
| Price | $65.97 | $40.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $57.75 | $39.00 |
| AVG Volume (30 Days) | ★ 1.3M | 1.0M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.60 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.12 | N/A |
| Revenue Next Year | $11.40 | N/A |
| P/E Ratio | $49.98 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.82 | $12.31 |
| 52 Week High | $85.83 | $48.40 |
| Indicator | COCO | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.21 | 55.70 |
| Support Level | $65.11 | $29.03 |
| Resistance Level | $69.59 | $43.93 |
| Average True Range (ATR) | 3.87 | 2.49 |
| MACD | -0.58 | -0.31 |
| Stochastic Oscillator | 4.48 | 42.60 |
The Vita Coco Co Inc is a plant-based functional hydration platform. Its products include Vita Coco Coconut Water, Private Label including coconut water and oil, and Other including Runa, Ever & Ever, and PWR LIFT product offerings, Vita Coco product extensions beyond coconut water, such as Vita Coco Sparkling, coconut milk products, and others. The company has two segments: The Americas segment which comprises of operations in the U.S. and Canada; and The International segment that comprises of operations in Europe, the Middle East, Africa and the Asia Pacific regions. The Americas segment derives maximum revenue. Geographical presence of the company is in United States, United Kingdom and All other countries.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.